420 related articles for article (PubMed ID: 32899891)
1. Immunotherapy in Small Cell Lung Cancer.
Esposito G; Palumbo G; Carillio G; Manzo A; Montanino A; Sforza V; Costanzo R; Sandomenico C; La Manna C; Martucci N; La Rocca A; De Luca G; Piccirillo MC; De Cecio R; Botti G; Totaro G; Muto P; Picone C; Normanno N; Morabito A
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899891
[TBL] [Abstract][Full Text] [Related]
2. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
3. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
5. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Zhang W; Gu J; Bian C; Huang G
Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
[No Abstract] [Full Text] [Related]
6. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
[TBL] [Abstract][Full Text] [Related]
8. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
[TBL] [Abstract][Full Text] [Related]
9. The role of immunotherapy in small cell lung cancer.
Calles A; Aguado G; Sandoval C; Álvarez R
Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
[TBL] [Abstract][Full Text] [Related]
10. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.
Sands J; Subramanian J
Front Oncol; 2023; 13():1161931. PubMed ID: 38221913
[TBL] [Abstract][Full Text] [Related]
11. Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
Armstrong SA; Liu SV
Curr Oncol Rep; 2020 Feb; 22(2):20. PubMed ID: 32034529
[TBL] [Abstract][Full Text] [Related]
12. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
[TBL] [Abstract][Full Text] [Related]
13. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
Liu X; Xing H; Liu B
Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of immunotherapy in small cell lung cancer.
Barrows ED; Blackburn MJ; Liu SV
Semin Cancer Biol; 2022 Nov; 86(Pt 3):868-874. PubMed ID: 35192928
[TBL] [Abstract][Full Text] [Related]
16. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC).
Saltos A; Shafique M; Chiappori A
Front Oncol; 2020; 10():1074. PubMed ID: 32766139
[TBL] [Abstract][Full Text] [Related]
17. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
19. The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.
Tsiouprou I; Zaharias A; Spyratos D
Can Respir J; 2019; 2019():6860432. PubMed ID: 31781314
[TBL] [Abstract][Full Text] [Related]
20. Chemo-immunotherapy as first-line treatment for small-cell lung cancer.
Farid S; Liu SV
Ther Adv Med Oncol; 2020; 12():1758835920980365. PubMed ID: 33414848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]